Q2 EPS Estimates for Haemonetics Reduced by Zacks Research

Key Points

• Zacks Research lowered Haemonetics’ Q2 2027 EPS estimate to $1.30 from $1.32, while projecting full-year 2027 EPS of $5.27 and full-year 2029 EPS of $6.20.
• Despite the estimate cut, other analysts raised their price targets, with targets ranging from $86 to $119. Haemonetics has a consensus rating of “Moderate Buy” and an average price target of $97.56.
• Haemonetics recently exceeded quarterly expectations, reporting $1.14 in EPS versus the $1.08 consensus and revenue of $339.38 million, up 5.5% year over year. Institutional investors own approximately 99.67% of the company’s stock.

Haemonetics Corporation (NYSE:HAE - Free Report) - Analysts at Zacks Research dropped their Q2 2027 earnings estimates for Haemonetics in a report released on Tuesday, August 25th. Zacks Research analyst Team now anticipates that the medical instruments supplier will post earnings of $1.30 per share for the quarter, down from their previous forecast of $1.32. The consensus estimate for Haemonetics' current full-year earnings is $5.28 per share. Zacks Research also issued estimates for Haemonetics' Q3 2027 earnings at $1.36 EPS, Q4 2027 earnings at $1.46 EPS, FY2027 earnings at $5.27 EPS, Q1 2028 earnings at $1.27 EPS, Q2 2028 earnings at $1.44 EPS, Q3 2028 earnings at $1.50 EPS, Q4 2028 earnings at $1.46 EPS, FY2028 earnings at $5.67 EPS, Q1 2029 earnings at $1.41 EPS and FY2029 earnings at $6.20 EPS.

Other equities research analysts have also issued reports about the company. Barrington Research lifted their price target on Haemonetics from $95.00 to $118.00 and gave the company an "outperform" rating in a research report on Wednesday, August 19th. BTIG Research raised their price objective on Haemonetics from $96.00 to $110.00 and gave the company a "buy" rating in a research report on Tuesday, August 18th. Robert W. Baird boosted their target price on shares of Haemonetics from $96.00 to $119.00 and gave the company an "outperform" rating in a report on Friday, August 21st. Weiss Ratings raised shares of Haemonetics from a "hold (c-)" rating to a "hold (c)" rating in a research report on Tuesday, August 11th. Finally, JPMorgan Chase & Co. increased their price target on shares of Haemonetics from $62.00 to $86.00 and gave the stock a "neutral" rating in a research note on Friday, August 7th. One analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have assigned a Hold rating to the stock. According to data from MarketBeat, Haemonetics presently has an average rating of "Moderate Buy" and a consensus price target of $97.56.

Haemonetics Stock Down 0.0%

HAE stock opened at $108.35 on Wednesday. Haemonetics has a fifty-two week low of $47.31 and a fifty-two week high of $109.57. The company has a market capitalization of $4.93 billion, a price-to-earnings ratio of 53.11, a price-to-earnings-growth ratio of 2.17 and a beta of 0.52. The business's 50 day moving average price is $83.00 and its two-hundred day moving average price is $69.11. The company has a debt-to-equity ratio of 1.40, a quick ratio of 1.91 and a current ratio of 3.08.

Haemonetics (NYSE:HAE - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The medical instruments supplier reported $1.14 EPS for the quarter, topping the consensus estimate of $1.08 by $0.06. The business had revenue of $339.38 million during the quarter, compared to analyst estimates of $327.86 million. Haemonetics had a net margin of 7.12% and a return on equity of 27.55%. Haemonetics's quarterly revenue was up 5.5% compared to the same quarter last year. During the same period last year, the business posted $1.10 earnings per share.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in HAE. California State Teachers Retirement System grew its stake in shares of Haemonetics by 7,550.6% in the second quarter. California State Teachers Retirement System now owns 4,024,650 shares of the medical instruments supplier's stock worth $301,849,000 after acquiring an additional 3,972,044 shares during the last quarter. AQR Capital Management LLC increased its holdings in shares of Haemonetics by 48.6% during the fourth quarter. AQR Capital Management LLC now owns 3,163,104 shares of the medical instruments supplier's stock valued at $253,523,000 after acquiring an additional 1,034,226 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its position in shares of Haemonetics by 994.7% in the 4th quarter. Arrowstreet Capital Limited Partnership now owns 1,380,102 shares of the medical instruments supplier's stock worth $110,615,000 after purchasing an additional 1,254,035 shares during the last quarter. Dimensional Fund Advisors LP raised its position in shares of Haemonetics by 21.3% in the 1st quarter. Dimensional Fund Advisors LP now owns 1,326,057 shares of the medical instruments supplier's stock worth $74,731,000 after purchasing an additional 233,119 shares during the last quarter. Finally, North Peak Capital Management LLC boosted its stake in Haemonetics by 204.4% in the 4th quarter. North Peak Capital Management LLC now owns 1,102,992 shares of the medical instruments supplier's stock worth $88,405,000 after purchasing an additional 740,626 shares in the last quarter. Hedge funds and other institutional investors own 99.67% of the company's stock.

More Haemonetics News

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks raised its FY2027 EPS forecast to $5.27 from $5.20, lifted Q4 2027 EPS to $1.46 from $1.42, increased Q1 2029 EPS to $1.41 from $1.33, and nudged FY2029 EPS to $6.20 from $6.19. These upgrades suggest improving expectations for Haemonetics’ longer-term earnings growth.
• Neutral Sentiment: The revisions are relatively small and apply primarily to periods two or more years ahead. Zacks continues to project FY2028 EPS of $5.67 and FY2029 EPS of $6.20, indicating an earnings-growth trajectory but limited near-term change to the broader outlook.
• Negative Sentiment: Zacks reduced estimates for Q2 2027 EPS to $1.30 from $1.32, Q3 2027 EPS to $1.36 from $1.37, Q1 2028 EPS to $1.27 from $1.31, Q2 2028 EPS to $1.44 from $1.45, Q3 2028 EPS to $1.50 from $1.52, and FY2028 EPS to $5.67 from $5.69. The cuts point to some pressure on intermediate-term earnings expectations.

About Haemonetics

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company's offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company's product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source